» Articles » PMID: 19556315

The Development of Patient-reported Outcome Indices for Multiple Sclerosis (PRIMUS)

Overview
Journal Mult Scler
Publisher Sage Publications
Specialty Neurology
Date 2009 Jun 27
PMID 19556315
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Complex diseases such as multiple sclerosis (MS) present dilemmas over the choice of patient-reported outcome measures as no single scale can inform on all types of MS impact from the patient's perspective.

Objective: To develop an outcome tool, the Patient-Reported Indices for Multiple Sclerosis (PRIMUS), to assess MS symptoms, activities, and quality of life.

Methods: PRIMUS content was derived from qualitative interviews with UK MS patients and checked by clinical experts. Semi-structured cognitive debriefing interviews assessed scale face and content validity. PRIMUS scaling properties, reliability, and construct validity were assessed by a test-retest postal survey.

Results: Cognitive debriefing interviews (n = 15) demonstrated scale clarity, relevance, and comprehensiveness. The postal survey was completed by 135 patients with MS. After removal of misfitting items and those exhibiting differential item functioning, all scales fitted the Rasch model, confirming unidimensionality. For all scales, test-retest reliability exceeded 0.80. Scale scores were related to perceived MS severity, general health, and symptoms of depression. Moderate correlations were observed between PRIMUS and Nottingham Health Profile scores.

Conclusions: Clinicians and researchers can have confidence in scores obtained by respondents on the PRIMUS. The PRIMUS will aid the assessment of the impact of MS from the patient's perspective.

Citing Articles

The 27-Item Multiple Sclerosis Quality of Life Questionnaire: A New Brief Measure Including Treatment Burden and Work Life.

Beckmann H, Heesen C, Augustin M, Blome C Int J MS Care. 2022; 24(4):147-153.

PMID: 35875460 PMC: 9296051. DOI: 10.7224/1537-2073.2020-088.


Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study.

Paul F, Calabresi P, Barkhof F, Green A, Kardon R, Sastre-Garriga J Ann Clin Transl Neurol. 2021; 8(12):2235-2251.

PMID: 34792863 PMC: 8670323. DOI: 10.1002/acn3.51473.


Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study.

Fernandez O, Izquierdo G, Aguera E, Ramo C, Hernandez M, Silva D Mult Scler J Exp Transl Clin. 2020; 6(3):2055217320957358.

PMID: 32974041 PMC: 7493256. DOI: 10.1177/2055217320957358.


The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study.

Ness N, Haase R, Kern R, Schriefer D, Ettle B, Cornelissen C J Med Internet Res. 2020; 22(3):e17921.

PMID: 32181745 PMC: 7109610. DOI: 10.2196/17921.


Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC.

Berger T, Brochet B, Brambilla L, Giacomini P, Montalban X, Vasco Salgado A Mult Scler J Exp Transl Clin. 2019; 5(4):2055217319887191.

PMID: 31832225 PMC: 6891011. DOI: 10.1177/2055217319887191.